Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 10/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31519869 | 0.87 | OPRD1 (0.64) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL31519870 | 0.86 | OPRD1 (0.66) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL31519873 | 0.85 | OPRD1 (0.62) | NTSR1OPRD1 | |
| SCHEMBL31519871 | 0.84 | OPRD1 (0.66) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL10005970 | 0.84 | KISS1R (0.58) | NTSR1NTSR2KISS1RMAPK8MAPK9 | |
| SCHEMBL8700587 | 0.84 | NTSR1 (0.63) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL9807257 | 0.84 | NTSR1 (0.62) | NTSR1NTSR2SORT1 | |
| SCHEMBL30906002 | 0.83 | SLC6A2 (0.57) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL9807268 | 0.83 | KDM1A (0.57) | OPRM1OPRK1KISS1R | |
| SCHEMBL30312779 | 0.83 | NTSR1 (0.72) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877715-B2 | Cytotoxic conjugates having neuropeptide Y receptor binding compound | IPSEN PHARMA S.A.S. (FR) | 2014-11-04 | — | — | US | disclosed |
| US-8877715-B2 | Cytotoxic conjugates having neuropeptide Y receptor binding compound | IPSEN PHARMA S.A.S. (FR) | 2014-11-04 | — | — | US | disclosed |
| US-20120010154-A1 | Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound | BIOMEASURE, INCORPORATED | 2012-01-12 | — | — | US | disclosed |
| US-20120010154-A1 | Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound | BIOMEASURE, INCORPORATED | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010154-A1 | Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound | NPY1R, NPY2R, NPY4R | NTSR1 6/4885NTSR2 11/4885SORT1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.